Jaguar Health Files 8-K: Regulatory, Other Events & Financials

TL;DR

Jaguar Health (JAGX) filed an 8-K on 3/31, covering Reg FD, other events, and financials. Check for updates.

AI Summary

Jaguar Health, Inc. filed an 8-K on April 4, 2025, reporting events as of March 31, 2025. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, formerly known as Jaguar Animal Health, Inc., is incorporated in Delaware and headquartered in San Francisco, California.

Why It Matters

This 8-K filing provides crucial updates on Jaguar Health's regulatory disclosures, other significant events, and financial statements, offering insights into the company's current operational and financial status.

Risk Assessment

Risk Level: medium — 8-K filings can contain material information, but the specific content here is broad, requiring further analysis to determine precise risk implications.

Key Numbers

• 001-36714 — SEC File Number (Identifies the company's filing with the SEC)
• 46-2956775 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

• Jaguar Health, Inc. (company) — Registrant
• Jaguar Animal Health, Inc. (company) — Former company name
• Delaware (jurisdiction) — State of incorporation
• San Francisco, California (location) — Principal executive offices
• March 31, 2025 (date) — Date of earliest event reported
• April 4, 2025 (date) — Filing date

FAQ

From the Filing

0000950170-25-051218.txt : 20250404 0000950170-25-051218.hdr.sgml : 20250404 20250404170009 ACCESSION NUMBER: 0000950170-25-051218 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250331 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250404 DATE AS OF CHANGE: 20250404 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 25815613 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 8-K 1 jagx-20250331.htm 8-K 8-K false 0001585608 0001585608 2025-03-31 2025-03-31   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025     Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 001-36714 46-2956775 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           200 Pine Street Suite 400   San Francisco , California   94104 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: (415) 371-8300     (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, Par Value $0.0001 Per Share   JAGX   The Nasdaq Stock Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐   Item 7.01 Regulation FD Disclosure. On March 31, 2025, Jaguar Health, Inc. (the “Company”) closed its previously announced private placement (the “Private Placement”), in which the Company issued approximately $3.4 million aggregate principal amount of convertible promissory notes (collectively, the “Notes”) and warrants to purchase up to 622,584 shares of the Company’s common stock to selected institutional and accredited investors.   Item 8.01 Other Events. On April 1, 2025, the Company issued a press release announcing the closing of the Private Placement. The press release, w